Evaluate the potential role of blood eosinophils as a biomarker—predictor of future risk and / or treatment response—in COPD

The primary aim of the proposed study is to explore the relationship between blood eosinophil count and future exacerbation risk in COPD and effect of preventative COPD therapy on eosinophil level. Additional analysis will also aim to investigate the stability of the phenotype, defined by change in eosinophils over time and in response to treatment.

Exploratory investigations will also seek to characterise features of COPD patients with eosinophilia in terms of their COPD stage and categorisation, comorbid conditions and other clinical characteristics (respiratory symptoms, past history of exacerbations, risk factors).
This study will be the first in a series of REG-funded studies designed to explore the relationship between blood eosinophil count, COPD disease status, COPD exacerbations and to explore its value and utility as a measureable marker of future risk in COPD.

In particular, this study aims to:

  • Establish the relationship between blood eosinophil count and:
    o Future COPD exacerbations.
    o Response to preventative COPD therapy; and
  • Investigate the stability of the phenotype, defined by change in eosinophils over time and in response to treatment.

Lead Investigator:
David Price
Research Team:
Antonio Anzueto
Alvar Augusti
Mona Bafadhel
Guy Brusselle
Alison Chisholm
Daryl Freeman
Rupert Jones
Nicolas Roche
Ian Pavord
Todor Popov
Alberto Papi
Dirkje S. Postma
Emilio Pizzichini
Dermot Ryan
Mike Thomas
Claus Vogelmeier

Status: Active Study
Support: Respiratory Effectiveness Group
Registration: ENCEPP/SDPP/492
Documents and Publications:
Protocol
Abstracts
Presentations
Final Publications
Additional Material